Lifecycle Analysis of Medicines Withdrawn, Restricted, or Label Updated Due to Safety Signals (2000–2025): A Retrospective Pharmacovigilance Study

The 25-year period between 2000 and 2025 represents the most consequential era in the history of modern pharmacovigilance. Across these decades, dozens of high-profile pharmaceutical agents were withdrawn from global markets, subjected to significant regulatory restrictions, or had their prescribing information substantially revised following the detection of previously unrecognised or underappreciated safety signals. These events — spanning early blockbuster withdrawals such as rofecoxib (Vioxx) in 2004, mid-era concerns around rosiglitazone and natalizumab, and more recent actions involving fluoroquinolones, valproate in pregnancy, and checkpoint inhibitor toxicity — collectively exposed profound and evolving systemic vulnerabilities in pre-approval clinical trial design, post-marketing surveillance infrastructure, and the regulatory frameworks governing the pharmaceutical lifecycle. This retrospective study systematically examines the lifecycle trajectories of pharmaceutical agents that experienced major regulatory safety actions between 2000 and 2025. Specifically, we analyse the nature of the underlying safety signals, the chronological gap between initial approval and regulatory action, the role of spontaneous adverse drug reaction (ADR) reporting systems and active surveillance, the influence of epidemiological evidence and clinical trial data, evolving regulatory reform across five successive quinquennia, and the downstream public health consequences of delayed or inadequate regulatory response. A comprehensive review of publicly available regulatory documents from the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and the WHO Uppsala Monitoring Centre (UMC) was conducted. Data from the FDA Adverse Event Reporting System (FAERS), EudraVigilance, VigiBase, and peer-reviewed literature indexed in PubMed/MEDLINE, Cochrane Library, and Embase were systematically retrieved for the period January 2000 to December 2025. A structured narrative synthesis methodology was employed, with cases organised by decade and mechanism of harm. Eighteen case studies spanning five pharmacological eras are presented. Early-period actions (2000–2005) included rofecoxib, cerivastatin, troglitazone, cisapride, and phenylpropanolamine. Mid-period actions (2006–2012) featured rosiglitazone, natalizumab, sibutramine, and rimonabant. Late-period actions (2013–2019) encompassed fluoroquinolone safety communications, valproate restrictions in women of childbearing potential, codeine restrictions in children, and dronedarone label updates. Recent actions (2020–2025) addressed hydroxychloroquine revocation for COVID-19, ranitidine (Zantac) global withdrawal due to NDMA contamination, fluoroquinolone aortic aneurysm warnings, and immune-related adverse events from checkpoint inhibitors. The mean time between initial approval and definitive regulatory action across all cases was 6.3 years (range: 0.3–18.7 years). Cardiovascular toxicity (27.8%), hepatotoxicity (16.7%), neuropsychiatric effects (16.7%), metabolic and endocrine toxicity (11.1%), carcinogenic contamination (11.1%), and miscellaneous organ-specific harms (16.7%) were the principal categories identified. The 25 years from 2000 to 2025 witnessed both catastrophic pharmacovigilance failures and remarkable regulatory evolution. The FDA Amendments Act of 2007, the EU pharmacovigilance legislation of 2010–2012, the Sentinel Initiative, real-world evidence integration, and the emergence of structured benefit–risk frameworks represent genuine advances. Yet recurring patterns of delayed signal action, inadequate communication of risk to patients and prescribers, and industry transparency failures persist. This analysis provides a longitudinal evidence base for continued reform of pharmacovigilance systems in the era of precision medicine, biologics, and accelerated regulatory pathways.